-
SK Life Science Supports SUDEP Awareness Efforts Through Partnership with CURE Epilepsy and The Cameron Boyce Foundation
SK Life Science to Match Donations Up to $10,000 to Advance SUDEP Research, Awareness, and Education Release Highlights: SK Life Science to match donations to CURE Epilepsy up to $10,000 Supporting SUDEP awareness efforts with CURE Epilepsy and The Cameron Boyce Foundation Raising… Source: Read More
-
Unlocking the Future: 10 Research Frontiers in Child Health
Charting a New Path for Pediatric Science The landscape of pediatric medicine is rapidly evolving. A recent report highlights 10 critical research opportunities identified by the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). These areas are specifically targeted to address the most pressing challenges in child health and development,…
-
Revolutionizing Spine Care: Sharp Biomedical Secures Pre-Seed Funding to Transform Chronic Pain Treatment
A New Frontier in Outpatient Spine Care In a significant move for medical technology, Sharp Biomedical has officially announced the successful closing of its pre-seed funding round. Led by gener8tor, this investment marks a pivotal step in the company’s mission to refine and advance outpatient spine procedures. Targeting Early-to-Mid Stage Chronic Pain Chronic back pain…
-
Raymond Douglas, MD, PhD, Unveils Research on Six-Week Teprotumumab Dosing to Help Protect Hearing
LOS ANGELES, Oct. 12, 2026 /PRNewswire/ — Raymond Douglas, MD, PhD, a lead scientist behind the first FDA-approved treatment for thyroid eye disease (TED) and a 2026 ASOPRS Outstanding Contribution Award recipient, presented research at the American Society of Ophthalmic Plastic and… Source: Read More
-
Kexing Biopharm Makes a Strong Impression at CPhI Milan 2024
Innovation and Global Expansion At the recently concluded CPhI Milan 2024, one of the world’s most prestigious pharmaceutical industry gatherings, Kexing Biopharm showcased its commitment to global innovation and strategic international partnerships. The company’s presence at the event served as a major platform for highlighting its advanced biopharmaceutical capabilities. Strengthening International Ties Kexing Biopharm leveraged…
-
A New Era for Patient Safety: The Joint Commission Recognizes Genomic Surveillance in Hospitals
Transforming Infection Control In a significant move toward modernizing healthcare safety, The Joint Commission has officially recognized the vital role of genomic surveillance in identifying and managing disease transmission within hospital environments. By integrating advanced molecular diagnostics, healthcare facilities can now track pathogens with unprecedented precision, effectively transforming how we respond to healthcare-associated infections (HAIs).…
-
Unlocking the Code of Neurodegeneration: Stowers Scientist Joins $28.6 Million Research Initiative
A New Frontier in Brain Health Neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, remain some of the most complex challenges in modern medicine. A significant new development has emerged from the Stowers Institute for Medical Research, where scientist Jeffrey J. Pleiss, Ph.D., has been selected to participate in a massive, multi-institutional research effort. The $28.6…
-
Unlocking the Code: New $28.6 Million Initiative Targets Protein Misfolding in Neurodegenerative Disease
A Bold Step Forward in Neuroscience In a groundbreaking development for medical research, a Stowers Institute for Medical Research scientist has been selected to join a high-stakes, $28.6 million research initiative. This ambitious project aims to decode the complex biological mechanisms behind protein misfolding, a process increasingly recognized as a key driver in devastating neurodegenerative…
-
A New Frontier in Colon Cancer: First Patient Dosed in Phase III Cadonilimab Trial
Advancing Immunotherapy for Colon Cancer In a significant milestone for oncology research, Akeso, Inc. has officially announced that the first patient has been dosed in a global Phase III clinical trial evaluating cadonilimab. This study focuses on the perioperative treatment of patients with locally advanced colon cancer. Understanding Cadonilimab Cadonilimab is a novel, potentially first-in-class…
-
Kexing Biopharm Expands Global Reach at CPHI Milan 2024
A New Milestone in Global Partnerships Kexing Biopharm recently made a significant impact at CPHI Milan 2024, one of the world’s premier pharmaceutical industry events. The company utilized this global stage to showcase its latest advancements in biotechnology and forge new strategic alliances within the international market. Key Highlights from the Event During the exhibition,…
-
BioAffinity Technologies Secures $4 Million in New Strategic Financing
NASDAQ: $BIAF Strengthening the Path Forward BioAffinity Technologies, a company recognized for its innovative work in respiratory diagnostics, has officially announced the successful closing of a $4 million registered direct financing. This capital raise, facilitated by WallachBeth Capital, marks a significant milestone for the firm as it continues to advance its commercial and operational goals.…
-
Antengene to Present Latest Preclinical Results of ATG-207 (CD3-TGF Bifunctional Fusion Protein) at ACR 2026
SHANGHAI and HONG KONG, Oct. 8, 2026 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for… Source: Read More
-
Vinci Pharmaceuticals Secures Over $8 Million in Series A Funding for EpiPlant Platform
A Major Milestone for Drug Delivery Innovation Vinci Pharmaceuticals Inc. has officially announced the successful completion of its Series A financing round, securing more than $8 million USD. This significant capital injection marks a pivotal moment for the company as it moves to accelerate the development of its proprietary technology. Advancing the EpiPlant Platform The…
-
Empowering the Next Wave of Breakthroughs: MassChallenge Launches $2 Million Innovation Fund
A New Milestone for Startup Support MassChallenge, the global network for innovators, has reached a significant milestone in its mission to support high-growth startups. With the announcement of the MC Innovation Fund, the organization is taking a major step toward providing the financial resources necessary to bridge the gap between early-stage development and scalable market…
-
A Major Milestone: Okami Medical Expands Use for the LOBO Vascular Occluder
Advancing Minimally Invasive Care Okami Medical, a leader in the development of innovative interventional medical technologies, has announced a significant milestone. The company has received an expanded indication from the U.S. Food and Drug Administration (FDA) for its LOBO Vascular Occluder, a device designed to change the landscape of peripheral vascular interventions. What This Means…
-
A Potential Breakthrough in Oral Cancer: PRV-111 and the Shift Toward Non-Surgical Treatment
The Search for Alternatives in Oral Cancer Care For patients diagnosed with early-stage oral cancer, surgery has long been the standard of care. While effective, surgery in the oral cavity can often result in significant functional and aesthetic challenges. Recently, Provention Bio, Inc., a subsidiary of Sanofi, provided a clinical update on their ongoing Phase…
-
A New Horizon: How the Schizophrenia Treatment Landscape is Evolving (2026-2036)
The Future of Schizophrenia Care The landscape for treating schizophrenia is poised for a significant transformation over the next decade. According to a recent report by DelveInsight, the market is expected to gain substantial momentum between 2026 and 2036, driven by an influx of innovative therapeutic options designed to better manage the complexities of the…
-
Clarivate Finalizes Sale of Life Sciences & Healthcare Segment: A New Chapter Begins
NYSE: $CLVT Strategic Realignment for Future Growth Clarivate Plc has officially announced the completion of the sale of its Life Sciences & Healthcare segment. This major divestiture marks a significant milestone in the company’s ongoing strategic transformation, aimed at streamlining operations and sharpening its focus on core business pillars. Key Takeaways from the Transaction By…
-
Kedrion to be Honored at Premier, Inc.’s Annual Supplier Innovation Celebration at the 2026 Breakthroughs Conference and Exhibition
QIVIGY® will be recognized as an innovative healthcare solution advancing care for patients in need of IVIG therapy FORT LEE, N.J., Oct. 6, 2026 /PRNewswire/ — Kedrion Biopharma today announced that it will be honored during Premier’s annual Supplier Innovation Celebration at its 2026… Source: Read More
-
Advancing Type 1 Diabetes Care: Mozart Therapeutics Shares New Data on MTX-101
A New Frontier in Autoimmune Research At the 62nd EASD Annual Meeting, Mozart Therapeutics took center stage to share critical updates regarding their lead therapeutic candidate, MTX-101. This presentation marks an important milestone for the company as they continue to investigate novel ways to treat autoimmune diseases, specifically focusing on Type 1 Diabetes (T1D). Understanding…
-
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the… Source: Read More
-
Advancing Women’s Health: AlloSource Launches UroConnex Fascia
A New Standard in Pelvic Reconstructive Surgery AlloSource, a leader in the advancement of regenerative medicine, has officially expanded its portfolio of allografts with the launch of UroConnex Fascia. This innovative product is specifically designed to support surgeons performing complex procedures in the field of women’s health. Understanding UroConnex Fascia UroConnex Fascia is an allograft—tissue…
-
SIBIONICS et PharmaSens explorent de nouvelles perspectives pour l’administration automatisée d’insuline lors du congrès de l’EASD 2026
MILAN, 5 octobre 2026 /PRNewswire/ — Lors du congrès 2026 de l’Association européenne pour l’étude du diabète (EASD), SiBionics a présenté « See More, Act Earlier » (Voir plus : agir plus tôt), qui établit un lien entre la surveillance continue et l’avenir de la prise en charge du… Source: Read More
-
A New Milestone in Blood Cancer Treatment: FDA Expands Approval for Jaypirca
NYSE: $LLY A New Therapeutic Option for CLL/SLL Patients The landscape of blood cancer treatment has taken a significant step forward. The U.S. Food and Drug Administration (FDA) has granted expanded approval for Jaypirca (pirtobrutinib), marking it as the first and only non-covalent BTK inhibitor available for patients with previously untreated chronic lymphocytic leukemia (CLL)…